Efficacy Between Different Two Self-Expanding Nitinol Stents For The Atherosclerotic Femoro-Popliteal Arterial Disease (SENS-FP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Korea University Guro Hospital
Sponsor:
Information provided by (Responsible Party):
Seung Woon Rha, Korea University Guro Hospital
ClinicalTrials.gov Identifier:
NCT01570803
First received: April 2, 2012
Last updated: October 9, 2013
Last verified: October 2013
  Purpose

Recent stent design improvements focus on decreasing stent fracture rates which can negatively impact patency rates by rearranging strut alignment. Although there have been several retrospective or registry studies for atherosclerotic femoropopliteal disease in the East, there have been few randomized control trial for comparison of stent fracture and primary patency between different nitinol stents. Smart stent has the peak-to-valley bridge and in-line interconnection. Medtronics company have claimed Complete's stent crowns have been configured to minimize crown to crown interaction, increasing the stent's flexibility without compromising radial strength. We made the hypothesis that the design of Complete-SE stent might be more fracture-resistant or effective for in-stent restenosis, compared with Smart stent. On the other hand, 2011 ESC guideline recommended that dual antiplatelet therapy with aspirin and a thienopyridine for at least one month is recommended after infrainguinal bare-metal-stent implantation. Recent meta-analysis has shown that the efficacy of cilostazol in the atherosclerotic femoropopliteal lesion was proven. However, still specific data regarding a variety of antiplatelet regimen are limited. To date, there is no the study for comparison between clopidogrel and cilostazole in patient undergone stent implantation in femoropopliteal lesion. In conclusion, the purpose of our study is to examine and compare Primary patency and stent fracture between different two-nitinol stents (S.M.A.R.T. CONTROL versus Complete SE) and to compare binary restenosis rate between clopidogrel and cilostazol in femoropopliteal arterial lesion.


Condition Intervention Phase
Peripheral Arterial Disease,
Atherosclerosis
Device: S.M.A.R.T CONTROL Stent
Device: Complete SE Stent
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)

Resource links provided by NLM:


Further study details as provided by Korea University Guro Hospital:

Primary Outcome Measures:
  • The rate of binary restenosis [ Time Frame: one year ] [ Designated as safety issue: No ]
    the rate of binary restenosis (stenosis of at least 50 percent of the luminal diameter) or PSVR ≥ 2.5 or zero (PSVR=peak systolic velocity within the area of stenosis divided by peak systolic velocity in a normal adjacent proximal artery segment) in the treated segment at 12 months after intervention as determined by catheter angiography or Duplex ultrasound


Secondary Outcome Measures:
  • stent fracture rate, clinical outcomes, angiographic outcomes, ankle-brachial index [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    1. stent fracture rate according to fracture grade (minor, moderate, severe
    2. Limb salvage rate free of above-the-ankle amputation
    3. Sustained clinical improvement rate at 12 month follow-up
    4. Repeated target lesion revascularization (TLR) rate
    5. Repeated target extremity revascularization (TER) rate
    6. Total re-occlusion rate
    7. Comparison of angiographic variables consisted of late loss and % restenosis
    8. Ankle-brachial index (ABI) at 12 months
    9. The rate of major adverse cardiovascular events (MACE) composed of all-cause death, myocardial infarction, and stroke at 12 months
    10. Incidence of geographic miss during stent deployment due to jumping and elongation
    11. The rate of binary restenosis or PSVR ≥ 2.5 or zero according to clopidogrel and cilostazol
    12. Major bleeding rate between clopidogrel and cilostazol group.


Estimated Enrollment: 346
Study Start Date: January 2013
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Complete SE Stent
study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
Device: Complete SE Stent
same to SMART CONTROL Stent
Active Comparator: SMART CONTROL Stent
same to Complete SE
Device: S.M.A.R.T CONTROL Stent
Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.

Detailed Description:

Five randomized, controlled trials failed to demonstrate any benefit of a stainless-steel stent over angioplasty alone. The nitinol stent has proven superior primary patency than balloon angioplasty in superficial femoral artery (SFA) lesions. Several studies reported stent fractures were associated with a higher risk of in-stent restenosis and reocclusion. In vitro, Stefan et al. reported the 7 different SFA stents showed differences in the incidence of high strain zones, which indicates a potential for stent fracture, as demonstrated by the mechanical fatigue tests. They claimed differences in stent design might play a major role in the appearance of stent strut fracture related to restenosis and reocclusion. Also, in retrospective study, Iida et al. reported there was significant difference in stent fracture between S.M.A.R.T. stent group and Luminexx stent group and primary patency was worse in those associated with stent fracture than in those without stent fractures. Recent stent design improvements focus on decreasing stent fracture rates which can negatively impact patency rates by rearranging strut alignment.

The design of self-expandible nitinol stents might be different depending on the developed time; The first-generation nitinol stents (e.g., LuminexxTM and SmartTM) showed a remarkably high rate of stent strut fracture. A second generation of slotted tube nitinol stents has been developed. These stents had a better flexibility, by reducing the number of connections between cells or crowns, and by configurating spiral orientation of these interconnections. Several studies reported that these nitinol stents are more fracture-resistant and more flexible, some of them providing superior patency rate (e.g., LifeTM and EverflexTM). However, the one of the important limitations to their studies is that those was the non-randomized study of relative small sample size or was confined to in-vitro. Upto date, the multicenter, randomized controlled trial for direct comparison of stent fracture and primary patency between two different nitinol stents has not been done except one study; SMART versus Luminexx stent. SMART and Luminexx stent have been classified into 1st generation self-expandable nitinol stent. Complete-SE stent of Medtronic company was different to Smart stent of Cordis company in that the configuration of interconnection of Complete-SE stent had peak-to-peak connection and more spiral orientation of interconnection, compared to mart stent. On the other hand, Smart stent has the peak-to-valley bridge and in-line interconnection. Medtronics company have claimed Complete's stent crowns have been configured to minimize crown to crown interaction, increasing the stent's flexibility without compromising radial strength. We made the hypothesis that the design of Complete-SE stent might be more fracture-resistant or effective for in-stent restenosis, compared with Smart stent.

On the other hand, to date, in previous many reports, the dual antiplatelet therapy consisted of aspirin and clopidogrel have proven to decrease the incidence of cardiovascular death, myocardial infarction, or revascularization without an increase in major bleeding in patients who underwent percutaneous coronary intervention regardless of stent type (bare metal stent or drug-eluting stent). In 2011 ESC (European society of cardiology) guideline, dual antiplatelet therapy with aspirin and a thienopyridine for at least one month is recommended after infra-inguinal bare metal stent implantation (Class I, Level C). However, there have been no the definite evidence or guideline for the optimal antiplatelet agents after stent implantation one month later. There have been many studies for the efficacy of thienopyridine in peripheral arterial disease. Also, With the potential benefit of cilostazol on vascular function in vitro, there have several previous efforts to prove the efficacy of cilostazol in patients undergoing endovascular therapy or stent implantation in peripheral arterial disease. However, still specific data regarding a variety of antiplatelet regimen are limited. Also, very few trials have effectively nor properly addressed the direct comparison for the efficacy and safety between clopidogrel and cilostazol. This trial designed to evaluate the efficacy and safety between aspirin plus clopidogrel versus aspirin plus cilostazol in patients undergoing stent implantation in femoropopliteal lesions.

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical criteria

    1. Age 20 years of older
    2. Symptomatic peripheral-artery disease with (Rutherford 2 - 6); moderate to severe claudication (Rutherford 2-3), chronic critical limb ischemia with pain while was at rest (Rutherford 4), or with ischemic ulcers (Rutherford 5-6)
    3. Patients with signed informed consent
  • Anatomical criteria

    1. Stenosis of >50% or occlusive atherosclerotic lesion of the ipsilateral femoropopliteal artery
    2. Patent (≤50% stenosis) ipsilateral iliac artery or concomitantly treatable ipsilateral iliac lesions (≤30% residual stenosis),
    3. At least one patent (less than 50% stenosed) tibioperoneal run-off vessel.

Exclusion Criteria:

  1. Disagree with written informed consent
  2. Major bleeding history within prior 2 months
  3. Known hypersensitivity or contraindication to any of the following medication: heparin, aspirin, clopidogrel, cilostazol, or contrast agent
  4. Acute limb ischemia
  5. Previous bypass surgery or stenting of the ipsilateral femoropopliteal artery
  6. Untreated inflow disease of the ipsilateral pelvic arteries (more than 50% stenosis or occlusion)
  7. Patients that major amputation ("above the ankle" amputation) has been done, is planned or required
  8. Patients with life expectancy <1 year due to comorbidity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01570803

Contacts
Contact: Seung-Woon Rha, MD, PhD 82-2-818-6387 swrha617@yahoo.co.kr
Contact: Sang-Ho Park, MD, PhD 82-41-570-3670 matsalong@schmc.ac.kr

Locations
Korea, Republic of
Korea University Guro Hospital Recruiting
Seoul, Korea, Republic of, 152-703
Contact: Seung Woon Rha, MD, PhD    82-2-818-6387    swrha617@yahoo.co.kr   
Contact: Sang Ho Park, MD, PhD    82-41-570-3670    matsalong@schmc.ac.kr   
Principal Investigator: Seung Woon Rha, MD, PhD         
Sub-Investigator: Sang Ho Park, MD, PhD         
Cardiovascular center, Korea University Guro Hospital Recruiting
Seoul, Korea, Republic of, 152-703
Contact: Seung-Woon Rha, MD, PhD    82-2-818-6387    swrha617@yahoo.co.kr   
Principal Investigator: Seung-Woon Rha, MD, PhD         
Sponsors and Collaborators
Korea University Guro Hospital
Investigators
Principal Investigator: Seung-Woon Rha, MD, PhD Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul, 152-703, Korea
  More Information

No publications provided

Responsible Party: Seung Woon Rha, Clinical Professor, Korea University Guro Hospital
ClinicalTrials.gov Identifier: NCT01570803     History of Changes
Other Study ID Numbers: SENS-FP
Study First Received: April 2, 2012
Last Updated: October 9, 2013
Health Authority: South Korea: Institutional Review Board

Keywords provided by Korea University Guro Hospital:
peripheral arterial disease,
atherosclerosis,
nitinol,
stents

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 28, 2014